Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study.

Conclusion: While both mirogabalin doses were well tolerated by most patients and showed potential for reducing pain associated with FM, the primary endpoint of significant pain reduction in patients on mirogabalin compared with placebo was not achieved in any of the three randomized controlled studies. Clinical trial registration: NCT02146430; NCT02187159; NCT02187471; and NCT02234583 (extension study). PMID: 31284771 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31284771?dopt=Abstract

Source: Current Medical Research and Opinion - July 11, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research